Goldman refreshes its gold stocks outlook for 2025
NORTH CHICAGO - AbbVie Inc. (NYSE:ABBV), a pharmaceutical giant with a market capitalization of $375 billion and current dividend yield of 3.08%, announced Friday that its board of directors has declared a quarterly cash dividend of $1.64 per share, according to a company press release.
The dividend will be payable on November 14, 2025, to stockholders of record as of the close of business on October 15, 2025.
AbbVie has increased its dividend by 310 percent since the company’s formation in 2013. The pharmaceutical company is a member of the S&P Dividend Aristocrats Index, which tracks companies that have raised their dividends annually for at least 25 consecutive years.
AbbVie focuses on several therapeutic areas including immunology, oncology, neuroscience and eye care, as well as products and services in its Allergan Aesthetics portfolio. The company maintains a "GOOD" overall financial health score and has demonstrated solid revenue growth of 6.05% over the last twelve months.
In other recent news, AbbVie announced its acquisition of Gilgamesh Pharmaceuticals’ lead investigational depression treatment, bretisilocin, for up to $1.2 billion. This transaction includes upfront payments and development milestones, expanding AbbVie’s psychiatric drug pipeline. The acquisition has led Raymond James to reiterate an Outperform rating for AbbVie, highlighting the drug’s novel mechanism as a 5-HT2A receptor agonist and 5-HT releaser, currently in Phase 2 clinical trials for major depressive disorder. Additionally, AbbVie reported promising results from its Phase 2 EPCORE NHL-6 trial, demonstrating the feasibility of administering epcoritamab in outpatient settings for patients with relapsed/refractory diffuse large B-cell lymphoma. The trial showed that 92% of patients successfully received their first full dose with manageable safety outcomes. Further positive results came from AbbVie’s drug upadacitinib (RINVOQ) in a Phase 3 clinical trial for severe alopecia areata, where significant hair regrowth was observed in treated patients. These developments underscore AbbVie’s ongoing efforts in expanding its treatment portfolio across various medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.